RxDoctor Payments DataLook up a doctor →

Athena Economides, MD

Allergy & Immunology · Wheaton, MDNPI 1902816325

Payments from drug & device makers

$11,219in general payments, 2019–2025

Across 509 payments — averaging $22.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • Octapharma USA, Inc.$1K
  • GSK$917
  • Biocryst US Sales Co., LLC$881
  • CSL Behring$863
  • Pharming Healthcare, Inc.$726
  • plus $5K from 35 others

What the payments were for

  • Consulting fees$1371%
  • Food & beverage$11,08199%
  • Education$20%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,219 in reported general payments places this provider in the 75th percentile of 105 allergy & immunology providers in Maryland.

See all allergy & immunology providers in Maryland

Medicare billing

Part B allowed, 2024
$882,683
Medicare patients
258
Services billed
30,278

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XolairOmalizumab16$88,469
Dupixent PenDupilumab12$46,547
Trelegy ElliptaFluticasone/Umeclidin/Vilanter22$41,374
Breo ElliptaFluticasone/Vilanterol43$19,892
Combivent RespimatIpratropium/Albuterol Sulfate12$6,639
Advair HfaFluticasone Propion/Salmeterol14$5,753
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate23$5,440
Fluticasone-SalmeterolFluticasone Propion/Salmeterol31$4,246
DuleraMometasone/Formoterol11$4,220
SymbicortBudesonide/Formoterol Fumarate11$3,814
Azelastine-FluticasoneAzelastine/Fluticasone16$3,535
Azelastine Hcl56$3,009
Wixela InhubFluticasone Propion/Salmeterol20$2,518
Fluticasone Propionate37$1,452
Albuterol Sulfate HfaAlbuterol Sulfate64$1,361

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Breo Ellipta$917$61,26665 claims
Boehringer IngelheimCombivent Respimat$74$6,63912 claims
MerckDulera$23$4,22011 claims
AstraZenecaSymbicort$1,411$3,81411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 105 allergy & immunology providers in Maryland.

Other allergy & immunology in Wheaton

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →